College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea.
College of Pharmacy and Natural Medicine Research Institute, Mokpo National University, Jeonnam, Republic of Korea.
Int J Nanomedicine. 2019 Oct 25;14:8509-8520. doi: 10.2147/IJN.S215835. eCollection 2019.
20(S)-Protopanaxadiol (PPD) has a higher anti-wrinkle effect than the other glycone forms of ginsenosides. However, as PPD has low solubility in water and a high molecular weight, it cannot easily penetrate the stratum corneum layer, which is the rate-limiting step of topical skin delivery. Thus, the objective was to enhance the topical skin deposition of PPD using an optimized nanostructured lipid carriers (NLC) formulation. NLC formulations were optimized using a Box-Behnken design.
NLC formulations were optimized using a Box-Behnken design, where the amount of PDD (X), volume of the liquid lipid (X), and amount of surfactant (X) were set as the independent variables, while the particle size (Y), polydispersity index (PDI) (Y), and entrapment efficiency (EE) (Y) were dependent factors. An in vitro deposition study was performed using Strat-M and human cadaver skin, while in vivo skin irritation effect of the NLC formulation was evaluated in humans.
An NLC was successfully prepared based on the optimized formulation determined using the Box-Behnken design. The particle size, PDI, and EE of the NLC showed less than 5% difference from the predicted values. The in vitro deposition of PPD after the application of the NLC formulation on a Strat-M artificial membrane and human cadaver skin was significantly higher than that of the controls. Moreover, NLC formulations with and without PDD were not skin irritants in a human study.
An NLC formulation for the topical delivery of PPD was successfully optimized using the Box-Behnken design, and could be further developed to enhance the topical skin deposition of PPD.
20(S)-原人参二醇(PPD)比其他人参皂苷的糖苷形式具有更高的抗皱效果。然而,由于 PPD 在水中的溶解度低且分子量高,它不易穿透角质层,这是局部皮肤递送的限速步骤。因此,目的是使用优化的纳米结构化脂质载体(NLC)制剂来提高 PPD 的局部皮肤沉积。使用 Box-Behnken 设计优化 NLC 制剂。
使用 Box-Behnken 设计优化 NLC 制剂,其中 PDD(X)的量、液体脂质(X)的体积和表面活性剂(X)的量作为自变量,而粒径(Y)、多分散指数(PDI)(Y)和包封效率(EE)(Y)是依赖因素。使用 Strat-M 和人体尸体皮肤进行体外沉积研究,同时在人体中评估 NLC 制剂的皮肤刺激性作用。
根据 Box-Behnken 设计确定的优化配方成功制备了 NLC。NLC 的粒径、PDI 和 EE 与预测值的差异小于 5%。与对照相比,NLC 制剂在 Strat-M 人工膜和人体尸体皮肤上应用后的 PPD 体外沉积显著更高。此外,在人体研究中,含有和不含有 PPD 的 NLC 制剂均无皮肤刺激性。
使用 Box-Behnken 设计成功优化了 PPD 的局部递送 NLC 制剂,并可进一步开发以提高 PPD 的局部皮肤沉积。